Trials / Completed
CompletedNCT01949103
TD-1607 MAD Study in Healthy Subjects
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TD-1607, a Glycopeptide-Cephalosporin Heterodimer Antibiotic, in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Theravance Biopharma · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
TD-1607, administered intravenously as multiple ascending doses, will be investigated in healthy subjects to assess its tolerability, safety, and pharmacokinetics.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TD-1607 | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2014-06-01
- Completion
- 2014-07-01
- First posted
- 2013-09-24
- Last updated
- 2021-01-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01949103. Inclusion in this directory is not an endorsement.